Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/121862
Title: HEALTH ECONOMICS OF PHARMACOGENETIC TESTING
Authors: DONG DI
Keywords: Health Economics, Medical Decision Making, Genetic Testing, Adverse Drug Reactions, Pharmacogenetics, Health Policy
Issue Date: 11-Aug-2015
Citation: DONG DI (2015-08-11). HEALTH ECONOMICS OF PHARMACOGENETIC TESTING. ScholarBank@NUS Repository.
Abstract: SOME COMMONLY USED MEDICATIONS CAN CAUSE A LIFE-THREATENING ADVERSE DRUG REACTION NAMED STEVENS-JOHNSON SYNDROME (SJS). THOUGH THE GENETIC RISK FACTORS HAVE BEEN WELL ESTABLISHED, ADOPTION OF PHARMACOGENETIC TESTING TO REDUCE SJS RISK IN CLINICAL CARE HAS BEEN SLOW. I CONDUCT HEALTH ECONOMIC EVALUATIONS TO INFORM CLINICAL AND REGULATORY DECISION MAKING ON WHETHER PHARMACOGENETIC TESTING SHOULD BE DONE TO REDUCE THE RISK OF SJS IN SINGAPORE. I FIRST ASSESSED THE COST-EFFECTIVENESS OF TWO PHARMACOGENETIC TESTS FROM A HEALTH SYSTEM PERSPECTIVE, AND FOUND THAT GENOTYPING EPILEPSY PATIENTS FOR HLA-B*1502 PRIOR TO CARBAMAZEPINE TREATMENT WAS HIGHLY COST-EFFECTIVE, WHEREAS GENOTYPING CHRONIC GOUT PATIENTS FOR HLA-B*5801 PRIOR TO ALLOPURINOL TREATMENT WAS NOT COST-EFFECTIVE IN SINGAPORE. I THEN MEASURED PATIENTS? PREFERENCES FOR PHARMACOGENETIC TESTING IN CHRONIC GOUT TREATMENT. RESULTS SUGGESTED THAT RISK OF SJS, COST OF GENOTYPING, COST OF GOUT TREATMENT, DOCTOR?S RECOMMENDATION AND CHOICE
URI: http://scholarbank.nus.edu.sg/handle/10635/121862
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Dong Di Dissertation.pdf3.65 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

171
checked on Jan 26, 2023

Download(s)

118
checked on Jan 26, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.